US2013252833A1PendingUtilityA1
Drg11-responsive (dragon) gene and uses thereof
Est. expiryAug 2, 2024(expired)· nominal 20-yr term from priority
C12Q 1/6841C12Q 1/66C12Q 1/68C07K 16/18G01N 2500/02C12N 2310/11C12Q 1/686G01N 33/6893C07K 2317/76G01N 33/53A61K 48/00A61K 38/1709G01N 2333/495C12N 15/113C07K 2317/92G01N 2333/47G01N 33/74C07K 2317/34G01N 33/57595
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention features methods and compositions useful for treating and diseases caused by a dysregulation of the BMP/GDF branch of the TGF-β signaling pathway. Also disclosed are methods for identifying compounds useful for such therapy.
Claims
exact text as granted — not AI-modified1 . A method for identifying a compound that modulates a TGF-β signaling pathway, said method comprising the steps of:
a. providing a sample comprising a DRAGON protein and a TGF-β signaling pathway member;
b. contacting said sample with a candidate compound; and
c. assessing the binding of said DRAGON protein to said TGF-β signaling pathway member in said sample in the presence of said candidate compound relative to binding in the absence of said candidate compound, wherein a compound that modulates binding of said DRAGON protein to said TGF-β signaling pathway member is identified as a compound that modulates a TGF-β signaling pathway.
2 - 41 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.